CR
CRVS.US Corvus Pharmaceuticals Inc
- Market cap
- USD 898M
- P/E
- -
- P/B
- 4.31x
- ROE
- -33.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRVS.US undervalued?
Graham numberThe Graham number of Corvus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Corvus Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Corvus Pharmaceuticals Inc yet.
Corvus Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, a…
Full company profileCorvus Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Corvus Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -594K | -842K | -847K | -743K | -632K | -460K | -367K | -151K | -85.0K | -105K | - |
| Operating Income | -37.0M | -56.5M | -49.2M | -48.9M | -43.8M | -38.6M | -32.6M | -23.4M | -27.5M | -43.0M | -74.0M |
| EBITDA | -36.4M | -55.7M | -48.4M | -48.1M | -43.1M | -42.8M | -40.9M | -26.9M | -62.2M | -15.2M | -66.2M |
| Net Income | -36.4M | -55.7M | -46.9M | -43.7M | -4.82M | -43.2M | -41.3M | -27.0M | -62.3M | -15.3M | -69.3M |
| EPS | -2.36 | -2.72 | -1.71 | -1.49 | -0.16 | -1.03 | -0.89 | -0.56 | -1.02 | -0.19 | -0.75 |
| Balance Sheet | |||||||||||
| Total Assets | 140M | 94.8M | 118M | 83.6M | 85.5M | 109M | 68.2M | 45.6M | 68.9M | 71.1M | 224M |
| Total Liabilities | 7.35M | 9.94M | 7.90M | 12.5M | 13.4M | 12.3M | 12.1M | 6.87M | 36.3M | 9.91M | 15.6M |
| Shareholders' Equity | 133M | 84.8M | 110M | 71.1M | 72.1M | 97.2M | 56.1M | 38.7M | 32.6M | 61.2M | 208M |
| Cash & Short-term Investments | 135M | 90.1M | 115M | 78.0M | 44.3M | 69.5M | 42.3M | 27.1M | 52.0M | 56.8M | 203M |
| Total Debt | - | - | - | 3.19M | 2.31M | 3.65M | 2.60M | 1.37M | 1.12M | 937K | 632K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.9M | -46.2M | -41.0M | -37.3M | -34.8M | -36.7M | -27.0M | -23.9M | -25.4M | -32.8M | -50.6M |
| Capital Expenditure | 2.20M | 266K | 355K | 25.0K | 76.0K | 5.00K | 269K | 34.0K | 0.00 | 174K | 985K |
| Free Cash Flow | -30.1M | -46.5M | -41.3M | -37.3M | -34.9M | -36.7M | -27.3M | -24.0M | -25.4M | -33.0M | -51.6M |
| Ratios | |||||||||||
| ROE | -27.4% | -65.6% | -42.5% | -61.5% | -6.7% | -44.5% | -73.6% | -69.9% | -191.3% | -25.0% | -33.3% |
| ROA | -26.0% | -58.7% | -39.7% | -52.3% | -5.6% | -39.5% | -60.5% | -59.3% | -90.4% | -21.5% | -31.0% |
| Debt to Equity | - | - | - | 0.04x | 0.03x | 0.04x | 0.05x | 0.04x | 0.03x | 0.02x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Corvus Pharmaceuticals Inc dividends
Corvus Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Corvus Pharmaceuticals Inc
- Insiders 3.97%
- Institutions 84.79%
- Public & others 11.24%
- Shares outstanding 84.4M
- Free float 73.0M
Top funds holding CRVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.41M | 2.85% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.94M | 2.31% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.61M | 1.91% | 0.00% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 802K | 0.95% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 781K | 0.93% | -11.03% | Sep 2026 |
| Fidelity Small Cap Index | 743K | 0.88% | +0.29% | Aug 2026 |
| Hood River Small-Cap Growth Instl | 707K | 0.84% | -4.96% | Jun 2026 |
| iShares Russell 2000 Growth ETF | 599K | 0.71% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 499K | 0.59% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 396K | 0.47% | +0.23% | Oct 2026 |
| Vanguard Russell 2000 ETF | 370K | 0.44% | -5.01% | Sep 2026 |
| Fidelity Extended Market Index | 343K | 0.41% | -5.44% | Sep 2026 |
| Vanguard Explorer Inv | 297K | 0.35% | +2.24% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 254K | 0.30% | +0.02% | Aug 2026 |
| SEB Läkemedelsfond A (SEK) | 227K | 0.27% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 192K | 0.23% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 192K | 0.23% | +0.11% | Sep 2026 |
| Emerald Growth A | 189K | 0.22% | 0.00% | Sep 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 182K | 0.22% | 0.00% | Oct 2026 |
| Principal SmallCap Growth I Instl | 178K | 0.21% | -0.56% | Sep 2026 |
Top institutions holding CRVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC | 7.17M | 8.50% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.14M | 8.47% | +15.88% | Jun 2026 |
| State Street Corp | 4.47M | 5.31% | +25.47% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.79M | 4.49% | +29.88% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.29M | 3.91% | +1.80% | Jun 2026 |
| Adams Street Partners LLC | 3.28M | 3.88% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 2.81M | 3.33% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 2.73M | 3.24% | +17.82% | Jun 2026 |
| Perceptive Advisors LLC | 2.67M | 3.16% | +16.36% | Jun 2026 |
| Deep Track Capital, LP | 2.49M | 2.96% | +0.02% | Jun 2026 |
| BRAIDWELL LP | 2.13M | 2.52% | +21.31% | Jun 2026 |
| Geode Capital Management, LLC | 1.85M | 2.20% | +8.23% | Jun 2026 |
| Foresite Capital Management VI LLC | 1.83M | 2.17% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.58M | 1.87% | +2.31% | Jun 2026 |
| Hood River Capital Management LLC | 1.57M | 1.86% | +17.73% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.34M | 1.59% | -46.19% | Jun 2026 |
| Boxer Capital Management, LLC | 1.10M | 1.30% | 0.00% | Jun 2026 |
| Catalio Capital Management, LP | 1.08M | 1.28% | +21.18% | Jun 2026 |
| Millennium Management LLC | 1.05M | 1.24% | +20.96% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 815K | 0.97% | +21.62% | Jun 2026 |
Corvus Pharmaceuticals Inc company profile
- Company name
- Corvus Pharmaceuticals Inc
- Ticker
- CRVS.US
- Exchange
- USA Stocks
- Listed since
- Mar 23, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- December
- Address
- 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 900 4520
- Website
- corvuspharma.com
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Corvus Pharmaceuticals Inc management
4- Dr. Richard A. Miller M.D.Co-Founder, President, CEO & Chairman of the Board · born 1951
- Dr. Peter A. Thompson FACP, M.D.Co-Founder & Independent Director · born 1960
- Mr. Leiv LeaChief Financial Officer · born 1954
- Dr. William Benton Jones Ph.D.Senior Vice President of Pharmaceutical Development · born 1966